Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) Stock

Share on StockTwits

Tandem Diabetes Care Inc (NASDAQ:TNDM) EVP Brian B. Hansen sold 15,000 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $62.97, for a total transaction of $944,550.00. Following the completion of the transaction, the executive vice president now directly owns 17,991 shares of the company’s stock, valued at $1,132,893.27. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

TNDM opened at $57.11 on Friday. Tandem Diabetes Care Inc has a 12-month low of $26.40 and a 12-month high of $74.81. The company has a current ratio of 2.53, a quick ratio of 2.21 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $3.51 billion, a PE ratio of -22.40 and a beta of 0.33. The firm has a 50 day moving average of $63.64 and a two-hundred day moving average of $62.33.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.20. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The company had revenue of $93.26 million during the quarter, compared to analyst estimates of $69.95 million. During the same period last year, the firm posted ($0.33) EPS. Tandem Diabetes Care’s revenue for the quarter was up 173.2% compared to the same quarter last year. As a group, analysts predict that Tandem Diabetes Care Inc will post -0.65 EPS for the current fiscal year.

TNDM has been the subject of several research analyst reports. Oppenheimer increased their price objective on shares of Tandem Diabetes Care from $80.00 to $84.00 in a research report on Friday, August 2nd. BidaskClub raised shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 23rd. UBS Group increased their price objective on shares of Tandem Diabetes Care from $53.00 to $66.00 and gave the company a “neutral” rating in a research report on Tuesday, April 30th. Svb Leerink initiated coverage on shares of Tandem Diabetes Care in a research report on Monday, May 13th. They issued an “outperform” rating and a $83.00 price objective for the company. Finally, Stifel Nicolaus increased their price objective on shares of Tandem Diabetes Care from $58.00 to $70.00 and gave the company a “hold” rating in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $68.38.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Tandem Diabetes Care by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 6,227,080 shares of the medical device company’s stock worth $401,771,000 after purchasing an additional 316,123 shares during the period. BlackRock Inc. grew its stake in shares of Tandem Diabetes Care by 2.1% during the 2nd quarter. BlackRock Inc. now owns 4,054,911 shares of the medical device company’s stock worth $261,622,000 after purchasing an additional 83,336 shares during the period. Eagle Asset Management Inc. grew its stake in shares of Tandem Diabetes Care by 24.4% during the 1st quarter. Eagle Asset Management Inc. now owns 1,307,033 shares of the medical device company’s stock worth $82,996,000 after purchasing an additional 256,595 shares during the period. Carillon Tower Advisers Inc. grew its stake in shares of Tandem Diabetes Care by 26.1% during the 1st quarter. Carillon Tower Advisers Inc. now owns 922,735 shares of the medical device company’s stock worth $58,593,000 after purchasing an additional 190,728 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Tandem Diabetes Care by 15.9% during the 2nd quarter. Renaissance Technologies LLC now owns 897,927 shares of the medical device company’s stock worth $57,934,000 after purchasing an additional 123,500 shares during the period. 79.75% of the stock is currently owned by institutional investors and hedge funds.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: How much money do you need to begin day trading?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lundin Mining Co.  Insider Nemesia S.a.r.l.  Acquires 150,000 Shares
Lundin Mining Co. Insider Nemesia S.a.r.l. Acquires 150,000 Shares
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc  Stock
Brian B. Hansen Sells 15,000 Shares of Tandem Diabetes Care Inc Stock
Osisko gold royalties Ltd  Director Sells C$897,627.00 in Stock
Osisko gold royalties Ltd Director Sells C$897,627.00 in Stock
Deciphera Pharmaceuticals Inc  Director Sells $917,325.00 in Stock
Deciphera Pharmaceuticals Inc Director Sells $917,325.00 in Stock
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Boston Advisors LLC Decreases Stock Holdings in Textron Inc.
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc  Stock
Sumedh S. Thakar Sells 6,980 Shares of Qualys Inc Stock


© 2006-2019 Ticker Report